


## Spain

This country fact sheet accompanies the EHC heat map and gives you further information on the country's progress over the various EHC surveys.

Here, you will see how the FVIII international units provision has evolved and compares to other countries. You will also find the same parameters as in the heat map.



Per capita	Change since previous survey: ▲ Improvement ▼ Decline		2009		2012		2015		2018
Organisation Comprehensive Care Centres (CCCs) Yes	International units	Factor VIII	4.46	_	0.00		0.00		0.00
of care Haemophilla Council or Co-ordinating Group Number of groups in decision-making on haemophilla care Number of groups choosing haemophilla treatment products National Tender for procurement of factor concentrates No	per capita	Factor IX	0.54	•	0.00		0.00		0.00
National Haemophilia Council or Co-ordinating Croup Number of groups in decision-making on haemophilia care Number of groups in decision-making on haemophilia care Number of groups choosing haemophilia treatment products National Tender for procurement of factor concentrates No	Organisation	Comprehensive Care Centres (CCC's)	Yes		Yes		Yes		Yes
Number of groups in decision making on haemophilia care Number of groups choosing haemophilia treatment products National Tender for procups choosing haemophilia treatment products National Tender for procupement of factor concentrates No	of care	Haemophilia Treatment Centres	Yes		Yes		Yes		Yes
Number of groups choosing haemophilia treatment products National Tender for procurement of factor concentrates  No N		National Haemophilia Council or Co-ordinating Group			Yes	•	No		
National Tender for procurement of factor concentrates  No N		Number of groups in decision-making on haemophilia care	0	<b>A</b>	2		2	_	0
Treatment Home Treatment		Number of groups choosing haemophilia treatment products	0	<b>A</b>	2		2	_	0
Regimens   % of people with haemophilia using home treatment   T6-100%   T6-100%   T6-100%   Some   Some   Some   Some   Prophylaxis treatment availability   Yes   Yes   Yes   Yes   T6-100%   T6		National Tender for procurement of factor concentrates	No		No		No		No
Treatment delivered to the patient's home Prophylaxis treatment availability Yes Yes Yes Some Prophylaxis treatment availability 76-100% 76-100% 76-100% 76-100% 76-100% Adults currently on prophy (%) 1-25% 1-25% 1-25% 26-50% Access to ITI (% of people with inhibitors) 76-99% 76-99% 100% 100% 100% 100% 100% 100% 100% 1	Treatment	Home Treatment	Yes		Yes		Yes		Yes
Prophylaxis treatment availability Children currently on prophy (%) Adults currently on prophy (%) Adults currently on prophy (%) Access to IT (% of people with inhibitors) Access to Emergency medicine and acute surgery Access to Emergency medicine and acute surgery Access to IT (% of people with inhibitors) Access to Emergency medicine and acute surgery Access to Infectious disease specialists (especially HiV) Access to IT (% of people with inhibitors) Access to IT (% of people with inhibitors Access to IT (% of people with inhibitors Access to	regimens	% of people with haemophilia using home treatment	76-100%		76-100%		76-100%		76-100%
Children currently on prophy (%) Adults currently on prophy (%) Adults currently on prophy (%) Access to ITI (% of people with inhibitors) Access to Emergency medicine and acute surgery Specialist services Paediatrics Infectious disease specialists (especially HIV) Hepatology Rheumatology Orthopaedics Physiotherapy Dentistry Obstetrics and Gynaecology Genetics Social and psychological support Pain management General surgery Urology Sometimes General surgery Urology Share of Expected Haemophilia A Haemophilia B Bleeding Disorder Prevalence Haemophilia P Rasma-derived factor concentrate Cryoprecipitate  Veryes Plasma Pl		Treatment delivered to the patient's home			Some		Some		Some
Adults currently on prophy (%) Access to III (% of people with inhibitors) Access to Emergency medicine and acute surgery specialist services  Rediatrics Paediatrics Phepatology Rheumatology Orthopaedics Physiotherapy Dentistry Obstetrics and Gynaecology Genetics Social and psychological support Pain management General surgery Urology Share of Expected Bleeding Disorder Prevalence VMD replacement Plasma Adults currently on prophy (%) Access to III (% of people with inhibitors) Access to III (% of people with inhibitors Access to III (% of people with inhibit		Prophylaxis treatment availability	Yes		Yes	•	Some	<b>A</b>	Yes
Access to ITI (% of people with inhibitors)  Access to Emergency medicine and acute surgery Specialist services  Paediatrics Infectious disease specialists (especially HIV) Hepatology Rheumatology Orthopaedics Physiotherapy Dentistry Obstetrics and Gynaecology Genetics Social and psychological support Pain management General surgery Urology Share of Expected Bleeding Disorder Haemophilla Pervalence Von Willebrand Disease Von Willebrand Excombinant factor concentrate Recombinant factor concentrate Cryoprecipitate VWD replacement Hearny Plasma  Access to ITI (% of people with inhibitors) T6-99% Tes Yes Yes Yes Yes Yes Yes Sometimes Ves Yes Yes Yes Yes Yes Yes Yes Yes Yes Y		Children currently on prophy (%)	76-100%		76-100%		76-100%		76-100%
Access to Emergency medicine and acute surgery Paecilatrics   Yes   Yes		Adults currently on prophy (%)	1-25%		1-25%	<b>A</b>	26-50%		26-50%
Paediatrics Infectious disease specialists (especially HIV) Hepatology Rheumatology Orthopaedics Physiotherapy Dentistry Obstetrics and Gynaecology Genetics Social and psychological support Pain management General surgery Urology Sometimes Someti		Access to ITI (% of people with inhibitors)	76-99%		76-99%	<b>A</b>	100%		100%
Infectious disease specialists (especially HIV) Hepatology Rheumatology Orthopaedics Orthopaedics Physiotherapy Dentistry Obstetrics and Gynaecology Genetics Social and psychological support Pain management General surgery Urology Share of Expected Haemophilia B Prevalence Vom Willebrand Disease Haemophilia Pasma-derived factor concentrate Recombinant factor concentrate Recombinant factor concentrate Never	Access to	Emergency medicine and acute surgery			Yes		Yes		
Hepatology Rheumatology Orthopaedics Orthopaedics Physiotherapy Dentistry Obstetrics and Gynaecology Genetics Social and psychological support Pain management General surgery Urology Share of Expected Bleeding Disorder Prevalence Von Willebrand Disease Haemophilia Pasma-derived factor concentrate Herapy DDAVP Plasma Hepatology Rheumatology Sometimes Pres Sometimes A Yes Sometimes Sometimes Sometimes A Yes Sometimes A Yes Sometimes A Yes A A Y	specialist services	Paediatrics			Yes		Yes		
Rheumatology Orthopaedics Orthopaedics Physiotherapy Dentistry Obstetrics and Gynaecology Genetics Social and psychological support Pain management General surgery Urology Share of Expected Bleeding Disorder Prevalence Vom Willebrand Disease Haemophilia Pasma-derived factor concentrate Herapy Plasma Never		Infectious disease specialists (especially HIV)			Yes		Yes		
Orthopaedics Physiotherapy Dentistry Obstetrics and Gynaecology Genetics Social and psychological support Pain management General surgery Urology Share of Expected Bleeding Disorder Prevalence Von Willebrand Disease Haemophilia Pasma-derived factor concentrate Recombinant factor concentrate Recombinant factor concentrate Cryoprecipitate  Vericate  Sometimes Someti		Hepatology			Yes		Yes		
Physiotherapy Dentistry Obstetrics and Gynaecology Genetics Social and psychological support Pain management General surgery Urology Share of Expected Bleeding Disorder Prevalence Von Willebrand Disease Haemophilia Pasma-derived factor concentrate Recombinant factor concentrate Cryoprecipitate  WD Plasma  Cryoprecipitate  Physiotherapy Dentistry Sometimes A Yes Sometimes Sometimes Sometimes Sometimes Sometimes Sometimes A Yes Sometimes Sometimes A Yes Sometimes A Yes Sometimes Sometimes A Yes A		Rheumatology			Sometimes		Sometimes		
Dentistry Obstetrics and Gynaecology Genetics Social and psychological support Pain management General surgery Urology Sometimes Bleeding Disorder Prevalence Von Willebrand Disease Haemophilia Pasma-derived factor concentrate Recombinant factor concentrate Cryoprecipitate  WWD replacement Plasma-derived factor concentrate therapy Plasma  DDAVP Plasma  DDAVP Plasma  DDAVP Plasma  Pes Sometimes  Yes Yes Yes Yes Yes Yes Yes Yes Yes		Orthopaedics			Sometimes		Sometimes		
Obstetrics and Gynaecology Genetics Social and psychological support Pain management General surgery Urology Share of Expected Bleeding Disorder Haemophilia A Bleeding Disorder Haemophilia Pasma-derived factor concentrate Herapy Plasma  Obstetrics and Gynaecology Genetics Yes Yes Sometimes Somet		Physiotherapy			Sometimes		Sometimes		
Genetics Social and psychological support Pain management General surgery Urology Sometimes Some		Dentistry			Sometimes		Sometimes		
Social and psychological support Pain management General surgery Urology Share of Expected Haemophilia A Bleeding Disorder Prevalence Von Willebrand Disease Haemophilia Pasma-derived factor concentrate Recombinant factor concentrate Always Herapy Plasma Plasma-derived factor concentrate Never		Obstetrics and Gynaecology			Yes		Yes		
Pain management General surgery Urology Share of Expected Bleeding Disorder Prevalence Von Willebrand Disease Haemophilia Pasma-derived factor concentrate Recombinant factor concentrate Cryoprecipitate  WWD replacement WWD replacement therapy Palsma Palsma Palsma Person derived factor concentrate Plasma Plasma Plasma Plasma Plasma Plasma-derived factor concentrate Never Plasma Plasma-derived factor concentrate Never Plasma Never		Genetics			Yes		Yes		
General surgery Urology  Share of Expected Haemophilia A Bleeding Disorder Haemophilia B Prevalence von Willebrand Disease Haemophilia Pasma-derived factor concentrate Haemophilia Recombinant factor concentrate Haemophilia Plasma Plasma Plasma-derived factor concentrate  WWD replacement Plasma-derived factor concentrate  WWD replacement Plasma-derived factor concentrate  Never		Social and psychological support			Sometimes		Sometimes		
Urology Share of Expected Haemophilia A Bleeding Disorder Haemophilia B Prevalence von Willebrand Disease Haemophilia Pasma-derived factor concentrate Recombinant factor concentrate Haemophilia Plasma Recombinant factor concentrate Recombinant fac		Pain management			Sometimes	<b>A</b>	Yes		
Share of Expected Haemophilia A Bleeding Disorder Haemophilia B Prevalence von Willebrand Disease 28% 20% 20% 20% Haemophilia Pasma-derived factor concentrate Always Alwa		General surgery			Yes	•	Sometimes		
Bleeding Disorder Prevalence von Willebrand Disease 28% 2% 2% 2% Haemophilia Pasma-derived factor concentrate Always Alwa		Urology			Sometimes		Sometimes		
Prevalence von Willebrand Disease 2%	Share of Expected	Haemophilia A	54%	•	36%	<b>A</b>			
Haemophilia Pasma-derived factor concentrate Always Alway	Bleeding Disorder	Haemophilia B	28%	•	20%	<b>A</b>	27%		
replacement Recombinant factor concentrate Always Always Always Always therapy Plasma Never Neve	Prevalence	von Willebrand Disease	2%	<b>A</b>	2%	<b>A</b>	2%		
therapy Plasma Never Ne	Haemophilia	Pasma-derived factor concentrate	Always		Always		Always		Always
Cryoprecipitate     Never     Never     Never     Never       VWD replacement therapy     Plasma-derived factor concentrate     Always     ▼ Rarely     ▲ Always       DDAVP     Always     Always       Plasma     Never     Never     Never	replacement	Recombinant factor concentrate	Always		Always		Always		Always
VWD replacement       Plasma-derived factor concentrate       Always       Rarely       ▲ Always         therapy       DDAVP       Always       Always       Always         Plasma       Never       Never       Never	therapy	Plasma	Never		Never		Never		Never
therapy DDAVP Always Always Plasma Never Never Never		Cryoprecipitate	Never		Never		Never		Never
Plasma Never Never Never Never	VWD replacement	Plasma-derived factor concentrate			Always	▼	Rarely	<b>A</b>	Always
Plasma Never Never Never Never	therapy	DDAVP			Always		Always		
Cryoprecipitate Never Never		Plasma			Never		Never		Never
		Cryoprecipitate			Never		Never		